[ad_1]
Radnor, Pennsylvania, July 31, 2021 (Global News Agency) – Kessler Topaz Meltzer & Check, LLP Law Firm announced that it has filed a securities fraud class action lawsuit against Athira in the Western District of Washington, U.S. Pharmaceutical Company (NASA) DAQ Stock Code:Atta) (“Athira”) represents a person who purchases or acquires Athira common stock: a) Based on and/or traceable to the registration statement and prospectus related to Athira’s September 2020 Initial Public Offering (“IPO”) (collectively referred to as the “Registration Statement”); and/or b) September 18, 2020 Between June 17, 2021, Included (“Class Hours”).
Deadline reminder: Investors who purchase or acquire Athira common stock Based on or traceable to the IPO and/or Yes during class, No later than August 24, 2021, Seeking to be appointed as the chief plaintiff representative of the collective. For more information or to learn how to participate in this lawsuit, please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453; Toll-free number (844) 887-9500; info@ktmc.com; Either Click on https://www.ktmc.com/athira-pharma-class-action-lawsuit?utm_source=PR&utm_medium=link&utm_campaign=athira
Athira is a late-stage clinical biopharmaceutical company focused on developing small molecules to restore neuronal health and prevent neurodegeneration. On September 18, 2020, Athira submitted…
The full story on Benzinga.com
[ad_2]
Source link
